Belle Health Tirzepatide Review: Cost, an FDA Warning Letter & Honest Verdict (2026)

Belle Health received a real, independently confirmed FDA warning letter — "Belle Health LLC dba Belle," MARCS-CMS #721795, dated February 20, 2026 — citing its own compounded semaglutide and tirzepatide product labels for identifying "Belle" as the compounder when, per the FDA, it is not. This review pulled the letter directly from FDA.gov rather than trusting a secondhand summary. Every fact here comes from the company's own published program and the FDA's own published letter.

The FDA warning letter, verified directly

This review independently confirmed a genuine FDA warning letter against Belle Health LLC dba Belle, MARCS-CMS #721795, dated February 20, 2026, pulled directly from fda.gov. The letter states, verbatim: "The compounded semaglutide and tirzepatide products displayed on your website identify 'Belle' on the pictured label, suggesting Belle is the compounder of those drugs when in fact it is not." This is functionally the identical violation the FDA cited against a different provider reviewed on this site, SkinnyRx (MARCS-CMS #717989) — a label falsely implying the retail brand itself compounds the drug, when a separate, unnamed facility actually does. Read the letter yourself at fda.gov before deciding whether it changes your calculus.

What Belle Health is (beyond the letter)

Belle Health is a national DTC telehealth platform, operating since 2017 and serving all 50 states. It's genuinely more transparent than most on one axis: it names five compounding pharmacy partners — Striker, Strive, OptioRx, Enovex, and Braun PharmaCare — where most competitors name none.

What Belle Health costs

Pricing is flat-rate: $119/month for semaglutide, $199/month for tirzepatide, with no escalation as you titrate to a higher dose. The $199 tirzepatide figure requires a 3-month bundle commitment. Free weekly registered-dietitian sessions are included.

The brand-vs-compounded question

Belle Health dispenses compounded tirzepatide, not the FDA-approved branded product — and the FDA's own warning letter directly addresses labeling that misrepresented who actually compounds it. Compounded tirzepatide is pharmacy-made, not itself an FDA-approved finished drug, and was not the specific product studied in the pivotal trials. See our guide to whether compounded tirzepatide is still legal in 2026 for the regulatory picture.

How the care model holds up

Belle Health's real strengths: five named compounding pharmacy partners, flat-rate pricing that doesn't rise with dose, free weekly dietitian sessions, an operating history since 2017, and LegitScript certification. The trade-offs are significant: a confirmed, real FDA warning letter citing misbranding — independently verified by this review directly against FDA.gov; the $199 tirzepatide rate requires a 3-month commitment; and using multiple compounding pharmacies means the exact formulation you receive may differ across orders. As with any GLP-1 program, weigh a real regulatory finding seriously before committing; tirzepatide carries labeled warnings for acute pancreatitis, gallbladder disease, and a boxed thyroid C-cell tumor warning — see our guides on Zepbound side effects, the gallbladder risk, and the thyroid cancer warning.

Does the drug work? (Separate from the provider)

Judge the provider on price, oversight and disclosure; judge the molecule on its trials. Tirzepatide's are strong — roughly 15–21% of body weight over 72 weeks in SURMOUNT-1¹, and better than semaglutide head-to-head² — but they were run on the brand drug at FDA-approved doses. Our tirzepatide evidence guide has the full picture.

The honest verdict

This review's most significant finding stands on its own: Belle Health has a real, independently verified FDA warning letter specifically addressing misleading claims about who compounds its product. Its named pharmacy partners and flat pricing are genuine positives, but read the FDA letter yourself before deciding whether it changes your calculus. If a confirmed clean regulatory record matters to you, compare it against ShedRx or CoreAge Rx. Not every warning-letter claim in this category survives a check: this site once carried an unconfirmed one against FMmeds, and the same company-column match against FDA's full index that returned Belle Health's letter returned nothing for FMmeds. That claim has been withdrawn and the correction published on its own review. See our best tirzepatide providers ranking for the full field.